Signs linked to worse results from a common lung cancer drug
Original title: Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This looked back at past studies of a drug already in use.
The short version
Cancer that has spread to the brain is linked to worse results from the lung cancer drug osimertinib.
What was studied. Researchers pooled eighteen studies of people with advanced lung cancer. All 4,070 people had an EGFR gene change and took osimertinib as their first treatment.
What they found. People whose cancer had spread to the brain or spinal cord did worse. So did people who were less able to care for themselves, and people whose cancer had spread to the liver. A gene change called EGFR L858R was linked to worse results than a change called exon 19 deletion.
What this means, and what it doesn't
What it could mean: If you take osimertinib, these signs may help your doctor know who needs closer watching. They do not change what the drug is or how it is given.
What it doesn't mean: This does not mean the drug fails for people with these signs. It was a review of studies already done, not a new treatment or a new test. The authors say it does not tell doctors who should get stronger first treatment. It is not a cure and not a promise about any one person.
Source: PubMed, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.